Technical Data
M1202A
Macrophage Inflammatory Protein 1 alpha, Recombinant, Human (MIP-1 alpha, CCL3)
5ug
20ug
20ug
|
Technical Data |
|
M1202A |
Macrophage Inflammatory Protein 1 alpha, Recombinant, Human (MIP-1 alpha, CCL3) |
5ug 20ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human MIP-1 is a single, non-glycosylated, polypeptide chain containing 70 amino acids and having a molecular mass of 7820 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be, Ala-Ser-Leu-Ala-Ala. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: UV spectroscopy at 280nm using the absorbency value of 0.9 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). Endotoxin: 0.1ng/ug (IEU/ug) of rHuMIP-1. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a standard solution of MIP-1 as a Reference Standard. Reconstitution: Reconstitute the lyophilized rHuMIP-1 in sterile 18M -cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. [Clinical significance of RANTES and MIP-1 alpha in acute rejection episode in kidney transplantation] Shi BB, Wang HJ, Wang JT, Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004 Feb;26(1):70-2 2. MIP-1 alpha and myeloma bone disease. Roodman GD, Choi SJ, Cancer Treat Res 2004;118:83-100 3. Estrogen decreases chemokine levels in murine mammary tissue: implications for the regulatory role of MIP-1 alpha and MCP-1/JE in mammary tumor formation. Fanti P, Nazareth M, Mineo M, Raiber L, Endocrine 2003 Nov;22(2):161-8 4. [Serum and cerebrospinal fluid concentration of inflammatory proteins MIP-1-alpha and MIP-1-beta and of interleukin 8 in the course of borreliosis] Grygorczuk S, Pancewicz S, Swierzbinska R, Neurol Neurochir Pol 2003 Jan-Feb;37(1):73-87 5. Constitutive patterns of RANTES, MCP-1 and MIP-1 alpha expression at the mRNA and protein level during postnatal development of the rat brain. Geppert AM, Folia Neuropathol 2003;41(2):79-88 6. Levels of macrophage inflammatory protein 1 alpha (MIP-1 alpha) and MIP-1 beta in intervillous blood plasma samples from women with placental malaria and human immunodeficiency virus infection. Chaisavaneeyakorn S, Moore JM, Othoro C, Nahlen BL, Clin Diagn Lab Immunol 2003 Jul;10(4):631-6.
|
||